UPL-LTD.
19.7.2021 08:35:11 CEST | Business Wire | Press release
nurture.farm – a digital platform for growers, farming communities and food systems, is scaling and expanding its global reach as a part of the OpenAg™ network. The OpenAg™ network was conceived by UPL Ltd , a world leader in sustainable agriculture.
The nurture.farm platform fosters resilient farmers, making agriculture simple, profitable and sustainable for generations to come through technology-led solutions covering every step of the farming life cycle. nurture.farm , which was incubated by UPL, will operate as an open platform in the supply of products, innovation and mechanisation.
Dhruv Sawhney, COO and Business Head, nurture.farm said:
“The impact of nurture.farm on farming communities represents significant progress in advancing our mission to reimagine sustainability for agriculture across the world and help farmers secure a brighter future. Our digital platform is helping farming communities that are facing a number of competing external risks and challenges including variable weather patterns, financial insecurity, and lack of access to information and mechanisation. We are democratising technology, creating a shared infrastructure and uniting farmers and buyers under a global community committed to driving sustainability. We look forward to taking our revolutionary platform to new markets, as we endeavour to change the game for farmers and make food systems more sustainable.”
“We are pleased to welcome nurture.farm to the OpenAg™ network, and excited for the role they will play in our mission to unlock opportunities for farmers, food security and sustainable agriculture worldwide,” says Carlos Pellicer – COO, UPL Ltd. “By increasing accessibility to the solutions, technologies, and services that growers need to thrive, nurture.farm is creating a truly customer-centric ecosystem that delivers on the promise of shared prosperity and feeds sustainable growth for all.”
Through a holistic approach, nurture.farm has developed a comprehensive ecosystem of integrated solutions to increase accessibility, connectivity and resilience, and secure sustainable outcomes. The key solutions include:
- farm – supports farmers at every step of the farming life cycle by driving precision agriculture at scale through crop health solutions, advisory services, farm level mechanisation & digitization.
- retail – enables retailers & farmers to purchase authentic and high-quality agricultural input products (crop protection, seeds, farm equipment, feeds, and more).
- trade – connects farmers and buyers through end-to-end traceability of sustainable practices, transparency of information, and convenient access to markets.
- sustain – drives sustainable agriculture globally through regenerative practices and reward farmers for adopting them
Launched in early 2020, nurture.farm has since grown both in scale and impact, now supporting over 1 million farmers and 50,000 retailers on its digital platform, with over 2.5 million acres of farmland serviced. The platform has been well received by users across India, and several promising pilot projects are underway in other key markets including the U.S., South Africa, Brazil and Australia.
As a part of its mission to create sustainable food systems, nurture.farm is encouraging regenerative agriculture practices through its selection of products, services, and projects. It is driving numerous new programs, including stubble burning avoidance programs, biological products, carbon credits and reward programs to advance this mission.
Jai Shroff, Global CEO of UPL Ltd. said:
“nurture.farm is one of the most exciting initiatives within the OpenAg™ network, unlocking opportunities for farmers and food systems worldwide, delivering shared prosperity for our growers and their communities, and supporting environmental sustainability. The success of nurture.farm’s operations in India, as well as its pilot projects further afield, demonstrate the value creation the platform provides. I look forward to supporting nurture.farm’s further expansion and impact.”
Notes to Editors:
About UPL
UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. We are a purpose-led company. Through OpenAg™, UPL is focused on facilitating progress for the entire agricultural value chain. We are building a network that redefines the way an entire industry thinks and works – open to fresh ideas, innovative ways and new answers as we strive towards our mission to make every single food product more sustainable.
As one of the largest agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. We are present in more than 130 countries, represented by more than 10,000 colleagues globally. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com and follow us on LinkedIn , Twitter , Instagram and Facebook
About OpenAg ™
OpenAg™ is an open network to create sustainable growth for all – no limits, no borders. Together we are reimagining sustainability, bringing all of the different players across the food system – from farmers to food producers to consumers - in the spirit of collaboration to change how the whole industry thinks, works and evolves. Through agility, creativity and cooperation, and from new technologies, seeds, and biological solutions, to digital platforms, training programmes, and partnerships, OpenAg™ is an open door, an open heart, and an open invitation to work together to build sustainable, resilient, beneficial food systems.
To learn more about OpenAg™ visit upl-ltd.com/our-story/open-ag
View source version on businesswire.com: https://www.businesswire.com/news/home/20210718005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
